Impact du retard de croissance intra-utérin sur la concentration sérique maternelle du PlGF (Placental Growth Factor) : une étude cas-témoin

De Falco, 2012, The discovery of placenta growth factor and its biological activity, Exp Mol Med, 44, 1, 10.3858/emm.2012.44.1.025 Hertig, 2010, New markers in preeclampsia, Clin Chim Acta Int J Clin Chem, 411, 1591, 10.1016/j.cca.2010.07.020 Kar, 2014, Role of biomarkers in early detection of preeclampsia, J Clin Diagn Res JCDR, 8, BE01 Torry, 1998, Preeclampsia is associated with reduced serum levels of placenta growth factor, Am J Obstet Gynecol, 179, 1539, 10.1016/S0002-9378(98)70021-3 Tsatsaris, 2010, Pathophysiology of preeclampsia, Ann Fr Anesth Reanim, 29, e13, 10.1016/j.annfar.2010.02.011 Boulanger, 2007, New insights in the pathophysiology of preeclampsia and potential therapeutic implications, Nephrol Ther, 3, 437, 10.1016/j.nephro.2007.07.001 Geyl, 2014, Links between preeclampsia and intrauterine growth restriction, Gynecol Obstet Fertil, 42, 229, 10.1016/j.gyobfe.2014.01.008 Bamfo, 2011, Diagnosis and management of fetal growth restriction, J Pregnancy, 2011, 640715, 10.1155/2011/640715 Zhang, 2015, Placental adaptations in growth restriction, Nutrients, 7, 360, 10.3390/nu7010360 Vayssière, 2015, Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians, Eur J Obstet Gynecol Reprod Biol, 193, 10, 10.1016/j.ejogrb.2015.06.021 Massoud, 2015, Chart for estimation of fetal weight 2014 by the French College of Fetal Sonography (CFEF), J Gynecol Obstet Biol Reprod (Paris) Saffer, 2013, Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia, Pregnancy Hypertens, 3, 124, 10.1016/j.preghy.2013.01.004 Lepais, 2014, Fetal thrombotic vasculopathy is associated with thromboembolic events and adverse perinatal outcome but not with neurologic complications: a retrospective cohort study of 54 cases with a 3-year follow-up of children, Placenta, 35, 611, 10.1016/j.placenta.2014.04.012 Levine, 2006, Soluble endoglin and other circulating antiangiogenic factors in preeclampsia, N Engl J Med, 355, 992, 10.1056/NEJMoa055352 Chappell, 2014, Short-term prediction of preeclampsia: how close are we?, Biomark Med, 8, 455, 10.2217/bmm.14.22 Livingston, 2001, Placenta growth factor is not an early marker for the development of severe preeclampsia, Am J Obstet Gynecol, 184, 1218, 10.1067/mob.2001.113877 Duhig, 2014, How placental growth factor detection might improve diagnosis and management of pre-eclampsia, Expert Rev Mol Diagn, 14, 403, 10.1586/14737159.2014.908121 Levine, 2004, Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med, 350, 672, 10.1056/NEJMoa031884 Powers, 2010, Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies, PloS One, 5, e13263, 10.1371/journal.pone.0013263 Kusanovic, 2009, A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia, J Matern Fetal Neonatal Med, 22, 1021, 10.3109/14767050902994754 Chappell, 2013, Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study, Circulation, 128, 2121, 10.1161/CIRCULATIONAHA.113.003215 Griffin, 2014, Clinical applications of biomarkers in preeclampsia, Biomark Med, 8, 459, 10.2217/bmm.14.19 Rana, 2012, Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia, Circulation, 125, 911, 10.1161/CIRCULATIONAHA.111.054361 Vaisbuch, 2011, Circulating angiogenic and antiangiogenic factors in women with eclampsia, Am J Obstet Gynecol, 204, 152.e1, 10.1016/j.ajog.2010.08.049 Sibiude, 2012, Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction, PloS One, 7, e50208, 10.1371/journal.pone.0050208 Chaiworapongsa, 2011, Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia, J Matern Fetal Neonatal Med, 24, 1187, 10.3109/14767058.2011.589932 Chaiworapongsa, 2013, Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia, Am J Obstet Gynecol, 208, 287.e1, 10.1016/j.ajog.2013.01.016 Benton, 2012, Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?, Am J Obstet Gynecol, 206, 163.e1, 10.1016/j.ajog.2011.09.019 Taylor, 2003, Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies, Am J Obstet Gynecol, 188, 177, 10.1067/mob.2003.111